Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma analysis at the eighth year

Publisher Website
Google Scholar
Abstract
All the patients in the study received skin tests with PPD (5TU) and 100 μg of the same TAA used for the immunotherapy at 1, 4, 6, 9, and 12 months postoperatively. Patients in both immunotherapy groups showed a tendency for a better disease-free interval and overall survival compared to those of the control, but these interval and beneficial therapeutic effects were statistically significant only in the Group III patients who had no hilar lymph node metastasis (T1N0 and T2N0). Although Group III was originally designated as a nonspecific immunotherapy group, retrospectively, it should be called a lowdose specific immunotherapy group because these patients actually received a total of 500 μg of TAA (as skin tests) and three doses of CFA at separate sites.